Presence of copy number aberrations and clinical prognostic factors in patients with acute myeloid leukemia : an analysis of effect modification by Mensah-Glanowska, Patrycja et al.
POLISH ARCHIVES OF INTERNAL MEDICINE 2020; 130 (4)346
genes. However, the presence of CNAs was as‑
sociated with the FLT3 D835 / FLT3TKD muta‑
tion (P = 0.02). A bidirectional interaction be‑
tween CNAs and the Eastern Cooperative On‑
cologic Group Scale (ECOG) performance status 
was also found, which appears to be somewhat 
surprising. The presence of CNAs in patients with 
good performance (ECOG ≤2) was found to be as‑
sociated with better outcome, while in patients 
in poor clinical condition (ECOG ≥3), it was con‑
nected with an increased risk of death. General‑
ly, the presence of CNAs as a genomic instability 
marker is an important factor adversely affecting 
survival in cancer patients. Considering the re‑
sults presented by Bănescu et al,1 it would be in‑
teresting to investigate how many CNAs were 
found and which genes were most frequently af‑
fected. The assessment of CNAs may be interest‑
ing in patients both with de novo and with re‑
lapsed AML. Furthermore, the longitudinal as‑
sessment of CNAs, both at diagnosis and in re‑
lapse, might expand our knowledge on AML che‑
mosensitivity and clonal disease evolution.
Nowadays, next ‑generation sequencing (NGS) 
technology provides important data for optimiza‑
tion and personalization of AML treatment, and 
it becomes increasingly widely available. Howev‑
er, MLPA might be considered as a complementa‑
ry tool to NGS. A recently described MLPA ‑based 
NGS technique uses MLPA products to construct 
a library that can be transferred into the NGS 
procedure. By using this approach, CNAs of tar‑
get genes may be detected with improved preci‑
sion on a large scale.4
In the study by Bănescu et al,1 complete remis‑
sion was achieved in 15% of patients. According to 
a recent study on survival in patients with AML 
treated with standard intensive chemotherapy, 
remission may be achieved in 70% of patients 
with de novo AML younger than 60 years and in 
50% of older patients, leading to a 5 ‑year over‑
all survival rate of 40% to 50% and 20% to 30% 
in younger and older patients, respectively.5 It 
To the editor We read with great interest the re‑
cent paper by Bănescu et al1 addressing the asso‑
ciation of copy number aberrations (CNAs) with 
European LeukemiaNet risk category, somatic 
mutations, clinical features, and overall survival 
in patients with acute myeloid leukemia (AML). 
The authors assessed the use of multiplex liga‑
tion–dependent probe amplification (MLPA) for 
analyzing the impact of CNAs on patient out‑
come. The presence of recurrent somatic muta‑
tions in the FLT3, NPM1, and DNMT3A genes was 
also assessed.1
Acute myeloid leukemia is a heterogenous dis‑
ease characterized by expansion of undifferenti‑
ated myeloid precursor cells, leading to impaired 
hematopoiesis and normal bone marrow failure. 
Leukemia progenitor cells acquire recurrent ge‑
netic abnormalities and/or distinct somatic mu‑
tations, known as driver mutations, which is im‑
portant in disease diagnosis and prognosis as well 
as impacts the efficacy of chemotherapy.2 Data on 
these abnormalities allow risk stratification and 
further precise classification of leukemia.3 Dele‑
tions, duplications, and other genomic rearrange‑
ments result in dosage imbalance of genes. The as‑
sessment of these relatively frequent abnormali‑
ties may increase our knowledge on the pathogen‑
esis of AML. Copy number aberrations are detect‑
ed using the gold standard array ‑based methods: 
comparative genomic hybridization and single 
nucleotide polymorphisms, while MLPA is a rel‑
atively new, cost ‑effective, accurate, and reliable 
technique for CNA detection.
Bănescu et al1 demonastrated an association 
between the presence of CNAs and adverse risk 
category in the European LeukemiaNet classifi‑
cation in patients with AML (P <0.0001). How‑
ever, in the univariate Cox regression analysis, 
the presence of CNAs was not found to predict 
death in the study cohort. There were also no 
differences in the survival rate in patients with 
and without CNAs among those with somat‑
ic mutations in the FLT3, NPM1, and DNMT3A 
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for the fast investigation of patients with AML 
at a low cost. In our study, we did not analyze 
separately our copy number aberrations (CNAs) 
due to the increased type of different CNAs. As 
we mentioned, 283 adult patients with AML were 
evaluated for CNAs and they were found in 90 
(31.8%) cases (64 cases with 1 CNA, 11 cases with 
2 CNAs, 15 cases with ≥3 CNAs).
Briefly, 6 cases with 17p or 17q deletion (TP53, 
IKZF3, UNC13D genes); 10 with CNAs for 5q, es‑
pecially 5q33 (EBF1, MIR145, MIR146A genes), 
12 with CNAs represented by deletions of 7p 
(IKZF1) or 7q (MET, DPP6, RELN), 5 with CNAs 
for 9p21.3 and 9p13.2 (MTAP, CDKN2A, CD‑
KN2B, PAX5 genes), 6 with CNAs for 2p24.3 
and 2p23.2 (MYCN, ALK genes), 6 patients with 
CNAs for 8q24.21 (MYC gene), 3 with CNAs for 
13q14 (RB1, MIR15A, DLEU2, DLEU1 genes), 
7 with CNAs on X chromosome, 2 with CNAs 
for 3p26.3 (GHL1 ‑5 gene), 2 with CNAs for 21q22 
(RUNX1 gene), 2 with CNAs for 21q11(HSPA13 
gene), 1 with CNAs for 10q23.31 (PTEN gene), 
2 with CNAs for 12p13 (ETV6, CCND2, MDM2 
genes), etc. As it may seem, we identified an in‑
creased number of different types of CNAs. Con‑
sidering the relatively small number of cases 
for each type of CNA, which was not sufficient 
to ensure the power of statistical analysis sepa‑
rately on each CNA, we were unable to perform 
statistical analysis for each CNA. Taking into ac‑
count that AML is characterized by chromosom‑
al abnormalities (including also translocations) 
and gene mutations, we recommend the use of 
MLPA analysis in addition to other cytogenet‑
ic and molecular techniques for AML patient 
investigation.
Our MLPA results presented in the paper are 
general and must be clinically interpreted with 
caution. The main objective of the mentioned 
paper was to assess the utility of a multiplex liga‑
tion–dependent probe amplification (MLPA) assay 
in AML. As it was already mentioned,1-3 we con‑
sider MLPA‑ and NGS ‑based techniques useful in 
the diagnosis of patients with AML due to the clin‑
ical impact of the genetic anomalies in AML, but 
also for precision medicine in AML. Besides, sev‑
eral molecular techniques can be useful in the di‑
agnosis of patients with AML, each of them cov‑
ering the limits of the other technique.3
Regarding the complete remission, it was con‑
sidered achieved in 15% of our patients while in 
the study by Medeiros et al,4 it is estimated that 
the remission may be achieved in 50% of old‑
er AML cases (>60 years). The discrepancies in 
the results may be explained by the fact that those 
cases with relapse after complete or partial remis‑
sion were included in the relapse group. More‑
over, we did not subcategorize our patients ac‑
cording to their age. Treatment modalities used 
in our patients were the standard ones, accord‑
ing to the patient’s age and comorbidities, with 
a low or high dose of so ‑called 2+3 or 7+3 regi‑
mens5 or a high dose with hematopoietic stem 
cell transplantation.
is possible that if the authors added more clini‑
cal data regarding treatment modalities used in 
the study cohort, we would be able to better un‑
derstand the impact of CNAs on risk assessment 
and outcome in patients with AML.
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published article regarding the multiplex ligation‑
‑dependent probe amplification (MLPA) utility in 
patients with acute myeloid leukemia (AML)2 and 
also for their constructive comments.
We agree with the authors that the MLPA ‑based 
next ‑generation sequencing (NGS) technology is 
a useful method that provides important data for 
optimization and personalization of AML treat‑
ment. We have to mention that for low and middle‑
‑income countries, it may be very difficult to sup‑
port the cost of MLPA ‑based NGS analysis. The cost 
of such analysis is lower if the analysis includes 
a large number of patients, while for 1 to 20 pa‑
tients, for example, the cost is increased. At the 
same time, the analysis report for such patients 
had to be ready as soon as possible, for optimiza‑
tion and personalization of AML treatment. Cur‑
rently, we are also investigating our AML patients 
by NGS analysis, trough research grants, but for 
financial reasons, we perform NGS analysis only 
when we have more AML samples to be included in 
each run (Ion PI chip). Unfortunately, in this situa‑
tion it may be too late for some patients with AML.
Regarding the MLPA technique, we agreed 
that it had several limitations, but it is useful 
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